Baseline characteristics of the ulcerative colitis patients from cohorts A and B
| (a) Cohort A | |||
| Characteristic | Responders (n = 8) | Non-responders (n = 16) | p Value |
| Male/female (%) | 4/4 (50/50) | 10/6 (62.5/37.5) | 0.67 |
| Median (IQR) age at first IFX (years) | 28.4 (24.3–41.8) | 45.8 (36.5–62.3) | 0.03 |
| Median (IQR) weight at first IFX (kg) | 72 (57.8–78.5) | 73.3 (68.5–80.3) | 0.41 |
| Median (IQR) duration of disease prior to first IFX (years) | 10.3 (4.1–17.3) | 7.3 (2.6–13.3) | 0.67 |
| Median (IQR) C-reactive protein at first IFX (mg/dl) | 1.65 (1–9.6) | 6.5 (2.9–19.1) | 0.09 |
| Median (IQR) Mayo score before first IFX | 10 (8.8–10) | 9.5 (8.8–10.3) | 0.95 |
| Concomitant medication at first IFX (%) | |||
| 5-Aminosalicylates | 5 (62.5) | 13 (81.3) | 0.36 |
| Corticosteroids | 2 (25) | 5 (31.3) | 1 |
| Azathioprine/6-mercaptopurine | 7 (87.5) | 8 (50) | 0.18 |
| Corticosteroids + immunosuppressants | 2 (25) | 1 (6.3) | 0.25 |
| Active smoking at first IFX (%) | 1 (12.5) | 1 (6.3) | 1 |
| (b) Cohort B | |||
| Responders (n = 12) | Non-responders (n = 10) | p Value | |
| Male/female (%) | 6/6 (50/50) | 4/6 (40/60) | 0.69 |
| Median (IQR) age at first IFX (years) | 39 (28.5–46.8) | 51.5 (36–59.8) | 0.34 |
| Median (IQR) weight at first IFX (kg) | 75 (70.5–87.3) | 69 (56–78.5) | 0.09 |
| Median (IQR) duration of disease prior to first IFX (years) | 12.3 (4.8–16.8) | 6.8 (3.8–11) | 0.35 |
| Median (IQR) C-reactive protein at first IFX (mg/dl) | 0.7 (0.5–1.4) | 1.35 (0.7–2.2) | 0.28 |
| Median (IQR) Mayo score before first IFX | 8.5 (7.8–9.3) | 10 (9–10.8) | 0.13 |
| Concomitant medication at first IFX (%) | |||
| 5-Aminosalicylates | 6 (50) | 6 (60) | 0.69 |
| Corticosteroids | 8 (66.7) | 5 (50) | 0.67 |
| Azathioprine/6-mercaptopurine | 4 (33.3) | 6 (60) | 0.39 |
| Corticosteroids + immunosuppressants | 2 (16.7) | 3 (30) | 0.62 |
| Active smoking at first IFX (%) | 1 (8.3) | 0 (0) | 1 |
IFX, infliximab; IQR, interquartile range.